Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR. van Dongen JJ, et al. Among authors: van der does van den berg a, van wering er. Lancet. 1998 Nov 28;352(9142):1731-8. doi: 10.1016/S0140-6736(98)04058-6. Lancet. 1998. PMID: 9848348
Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease.
Szczepański T, Beishuizen A, Pongers-Willemse MJ, Hählen K, Van Wering ER, Wijkhuijs AJ, Tibbe GJ, De Bruijn MA, Van Dongen JJ. Szczepański T, et al. Among authors: van dongen jj, van wering er. Leukemia. 1999 Feb;13(2):196-205. doi: 10.1038/sj.leu.2401277. Leukemia. 1999. PMID: 10025893 Clinical Trial.
Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH, Jacobs DC, Wijkhuijs AJ, Comans-Bitter WM, Willemse MJ, Hählen K, Kamps WA, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj, van wering er. Leukemia. 2002 Aug;16(8):1432-6. doi: 10.1038/sj.leu.2402636. Leukemia. 2002. PMID: 12145681
Detection of minimal residual disease in acute leukemia.
van der Velden VH, Boeckx N, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj, van wering er. J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):146-54. J Biol Regul Homeost Agents. 2004. PMID: 15471219 Review.
Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias: a new molecular target for detection of minimal residual disease.
Beishuizen A, de Bruijn MA, Pongers-Willemse MJ, Verhoeven MA, van Wering ER, Hählen K, Breit TM, de Bruin-Versteeg S, Hooijkaas H, van Dongen JJ. Beishuizen A, et al. Among authors: van dongen jj, van wering er. Leukemia. 1997 Dec;11(12):2200-7. doi: 10.1038/sj.leu.2400904. Leukemia. 1997. PMID: 9447841
Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease.
Szczepański T, Willemse MJ, Brinkhof B, van Wering ER, van der Burg M, van Dongen JJ. Szczepański T, et al. Among authors: van dongen jj, van der burg m, van wering er. Blood. 2002 Apr 1;99(7):2315-23. doi: 10.1182/blood.v99.7.2315. Blood. 2002. PMID: 11895762 Free article.
182 results